In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
 

EHJ – Cardiovascular Pharmacotherapy

Specific Focus on Clinical Cardiovascular Pharmacology

 

The European Heart Journal – Cardiovascular Pharmacotherapy (EHJ-CVP) is the official journal of the European Society of Cardiology and the ESC Working Group on Cardiovascular Pharmacotherapy. The journal reports on the interpretation and integration of new scientific developments  to improve the pharmacological treatment of patients with cardiovascular disease.

It publishes original articles on clinical research, with new and established drugs and methods, as well as meta-analysis and topical reviews.

Access your online journal

 

Fast Facts

  • Editor-in-chief: Stefan Agewall FESC, NO
  • Current volume: 6 (year 2020)
  • Issues per subscription: 4
  • Impact Factor 2018: 6.723

Subscriptions

Subscribe

Connect with us on Twitter

@ESC_Journals
Updates on latest articles

Updates on latest articles

 

Receive the table of contents in your mailbox.

Track topics and authors  important to you and receive articles in your mailbox.

Sign up

For Authors

Before being published, all manuscripts go through double-blind, peer review by experienced international experts.

Submit a Manuscript

Submit

Instructions for Authors

Find out more

Publisher Information

See more

Frequently Asked Questions

See more

Most recent articles from EHJ-CVP

06 Jan 2020
Focus on pharma in acute coronary syndrome
Author(s):Agewall S.
04 Dec 2019
After a long time, the new ESC Guidelines for the management of patients with supraventricular tachycardia are here
Author(s):Tamargo J.
09 Dec 2019
Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study
Author(s):Chang C, Chichareon P, Modolo R, et al.
12 Sep 2019
P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects
Author(s):De Filippo O, D’Ascenzo F, Raposeiras-Roubin S, et al.

 

 
About the ESC
Press and Media
Information
Follow us

         

 Contact us

© 2019 European Society of Cardiology. All rights reserved.